Join MitoAction and Dr. Jan Smeitink, CEO of Khondrion for our our March Expert Series presentation. MELAS spectrum (m.3243A>G) disorders belong to the most frequently encountered group of primary...
Join MitoAction and Acton Pharmacy’s Clinical Pharmacist, Ted Toufas as we revisit and provide the latest updates about the mito cocktail! The mito cocktail is one of the front-line...
Join MitoAction and Matthew Klein and Francesco Bibbiani from PTC Therapeutics for our November Mito Expert Series presentation titled, “PTC-743 (Vatiquinone) for the Treatment of Mitochondrial Disease With Associated Refractory...
A Conversation with Ultragenyx’s Chief Medical Officer, Camille Bedrosian to discuss Insights into Future LC-FAOD Research. Also hear from Ultragenyx’s Global Metabolic Dietitian, Bridget Reineking on How to Use...
Join MitoAction and Dr. Fran Kendall of VMP Genetics on May 1 for our May Monthly Mito Expert Series! Her topic will be: Medical Cannabis & Mito: Historical Perspectives, Mechanism of...
“Understanding the New Recommendations on the Safety of Drug Use in Patients with a Primary Mitochondrial Disease” Clinical guidance is often sought when prescribing drugs for patients with primary...
A conversation with compounding pharmacist Arthur Margolis from America’s Compounding Center, September 7, 2007 by teleconference.
Join us with Dr. Sumit Parikh, Director of the Cleveland Clinic Neurogenetics, Metabolic and Mitochondrial Disease program, and past president of the Mitochondrial Medicine Society. Learn more about the 2014-2015...
One of the front-line treatment approaches to a mitochondrial disease is to use a combination, unique to each patient based on symptoms and diagnosis, of vitamins and supplements such...